Contributing Author
in
AI & Digital
Startups & Deals
Clinical Trials
Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
KYORIN Pharmaceutical has adopted Elix Discovery, an AI-based drug discovery platform developed by Tokyo-based Elix. The system is designed to accelerate early-stage research by applying machine learning to compound profiling, molecular generation, and predictive modeling.
Innovatrix Capital has partnered with Opyl Limited’s TrialKey platform to embed predictive analytics into parametric insurance products designed to cover the financial risk of clinical trial failure. The approach combines risk transfer mechanisms with outcome probability modelling in an attempt …
Ginkgo Bioworks’ Datapoints unit, Inductive Bio, and Tangible Scientific have partnered to deliver a lab-in-the-loop workflow that ties AI-driven molecular design directly to experimental validation. The collaboration integrates predictive ADMET modeling, automated compound logistics, and rapid assay services, …
Molecular Devices has released an upgrade to its CellXpress.ai Automated Cell Culture System, adding rocking incubation and AI-driven workflow automation for brain organoid culture. The feature is designed to reduce the high manual workload of organoid maintenance and to …
Owkin and the Comprehensive Cancer Center of the Medical University of Vienna have entered a collaboration to deploy agentic AI tools in oncology research and care. The partnership will introduce Owkin’s AI copilot, Owkin K, into Vienna’s oncology …
Researchers at MIT and the Broad Institute have reported generative artificial intelligence systems capable of designing entirely new antibiotics, including a compound active against methicillin-resistant Staphylococcus aureus (MRSA). The study, published August 14 in Cell, describes two lead molecules— …
BioAge Labs has started human testing of BGE-102, an orally available NLRP3 inhibitor designed to cross the blood-brain barrier. The Phase 1 trial will evaluate safety, dosing, and biological activity, with early results expected by the end of 2025. …
Kriya Therapeutics has secured $313.3 million in new financing, according to a recent SEC filing. The filing did not outline neither the planned use of the funds, nor the names of the investors, specifying only that two parties contributed. …
Eli Lilly has entered into a collaboration with Boston-based Superluminal Medicines valued at up to $1.3 billion to discover small-molecule drugs for obesity and cardiometabolic diseases. The agreement gives Lilly exclusive rights to develop and commercialize compounds identified through Superluminal’s …
Schrödinger, founded in 1990 and known for its physics-based computational platform used in drug and materials discovery, has halted development of its experimental CDC7 inhibitor SGR-2921 after the drug was linked to two patient deaths in a phase 1 …